Dima Sobko / Shutterstock.com
Hedge fund manager Kyle Bass has filed another inter partes review (IPR), teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Diprivan, Patent Trial and Appeal Board, USPTO, Kyle Bass, Coalition for Affordable Drugs, Fresenius Kabi, IPR, Inter Partes Review